Ocrelizumab
Ocrevus (ocrelizumab) is an antibody pharmaceutical. Ocrelizumab was first approved as Ocrevus on 2017-03-28. It is used to treat multiple sclerosis in the USA. It has been approved in Europe to treat multiple sclerosis. The pharmaceutical is active against B-lymphocyte antigen CD20.
| Trade Name | Ocrevus |
|---|---|
| Common Name | Ocrelizumab |
| Indication | multiple sclerosis |
| Drug Class | Monoclonal antibodies: humanized, immunomodulating |
